Question Bank › Fresh evidence outrunning the reported numbers

Fresh evidence outrunning the reported numbers

Calls Tested
450
Answered YES
27
Hit Rate
6%
rare by design

Clearside Biomedical, Inc. (CLSD) — this company's answers

NO on the Q3 2022 call 2022-11-09 C
The model's full reasoning — Q3 2022 call → NOWe need to determine if management's case for the future rests on fresh, early, already-real developments whose full effect is still ahead. The call is about CLS-AX Phase 1/2a trial results. The trial data is recent, but is it a "business development" that is already real and beginning to contribute? The trial is a clinical trial, not a commercial product. The company is planning a Phase 2 trial. The results are from a clinical trial, which is a development, but the question asks about "operating facts" like orders, customers, shipments, etc. Clinical trial results are not exactly that. However, the question says "developments may take any form that fits the industry" - for a biotech, clinical trial results are a key development. But the key is: are these results "already real today" and are they "only the beginning" with most effect still ahead? Management says they are encouraged and will move to Phase 2, but the results are from a trial that is complete (the OASIS trial) and the extension is ongoing. The results are reported now, but the contribution to the company's future is not yet in the numbers - the company has no revenue from CLS-AX. So the trial results are a recent development that is real, and management says they give confidence to move forward. But does management explicitly say that the reported results understate the business as it now stands? They say they will report final extension data in Q1 2023 and are planning Phase 2. They don't say that the current results are just the beginning of a contribution that will be seen in future numbers. The question is about "operating facts" - the trial results are not operating facts like revenue or customers. The company is a clinical-stage biotech, so its "business" is developing drugs. The trial results are a milestone, but they are not a "development" that is "already producing" in the sense of generating revenue or activity. The question specifically mentions "actual orders, customers, shipments, openings, conversions, utilization, activity, or commitments in hand" - none of these apply. The trial results are a clinical data readout, which is a step in the pipeline. Management's forward case rests on the promise of the drug, but the drug is not yet approved or commercialized. So the answer is likely NO.

← Back to the full CLSD analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management repeatedly ground its case for the company's future in OPERATING FACTS THAT ARE BOTH FRESH AND EARLY — concrete business developments that (a) began, occurred, or first became visible only within roughly the last quarter or two, (b) are already real today (actual orders, customers, shipments, openings, conversions, utilization, activity, or commitments in hand — not pipeline, interest, or plans), and (c) are explicitly described by management as only the BEGINNING of their contribution, with most of their effect still ahead of the reported results? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent evidentiary posture across the call: the strongest support for where the company is heading consists of recently-arrived, already-real developments whose weight has not yet landed in the published numbers. The developments may take any form that fits the industry — new business recently won and now beginning to flow; a product, facility, capability, or offering that recently went live and is now producing its first real activity; customers or counterparties who recently started, expanded, or converted and are now ramping; recently secured commitments now entering delivery; or a recent operational change whose measurable results have just started appearing. What matters is that management (1) points to these developments as things that actually happened or started recently — described in the past or present tense with concrete substance, not as intentions; (2) treats them, individually or together, as meaningful to the company's trajectory relative to its current size; and (3) states, directly or plainly in substance, that the results just reported capture only a small share of what these developments are expected to contribute, so the reported period understates the business as it now stands. Answer NO if management's forward case rests mainly on market conditions, industry tailwinds, pipeline, opportunity size, or general optimism rather than on identifiable recent developments already producing. NO if the cited developments are plans, negotiations, pilots without results, or contingent on approvals, financing, or decisions not yet made. NO if the recent developments are already substantially reflected in the reported results, with no meaningful contribution still ahead. NO if the fresh facts are routine in scale for this company — the ordinary cadence of wins, openings, or orders this business always reports — with no sense that they step the company beyond its current level. NO if management describes recent developments but never conveys that their contribution is still mostly ahead of the numbers. NO if the call is chiefly explaining weakness, delays, or problems with previously promised developments. NO if the posture appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
HCKT The Hackett Group, Inc. Q1 2024 2024-05-08 C
ROCK Gibraltar Industries, Inc. Q1 2024 2024-05-01 B+
HUYA HUYA Inc. Q4 2023 2024-03-19 C
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
SCPH scPharmaceuticals Inc. Q3 2023 2023-11-08 B
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
CARS Cars.com Inc. Q1 2023 2023-05-06 B
BRX Brixmor Property Group Inc. Q1 2023 2023-05-02 A
SOL ReneSola Ltd Q3 2022 2022-12-01 C+
SYY Sysco Corporation Q1 2023 2022-11-01 C+
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
BXP Boston Properties, Inc. Q1 2022 2022-05-03 A
PRPO Precipio, Inc. Q3 2018 2018-11-19 D
GECC Great Elm Capital Corporation Q3 2018 2018-11-13 B
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
WES Western Midstream Partners, LP Q3 2018 2018-10-31 D
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
MKC McCormick & Company, Incorporated Q2 2018 2018-06-28 C+
MXL MaxLinear, Inc. Q2 2017 2017-08-08 C+
LIND Lindblad Expeditions Holdings, Inc. Q2 2017 2017-08-06 C
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
BP BP p.l.c. Q4 2016 2017-02-07 B+
ARAY Accuray Incorporated Q4 2016 2016-08-17 B
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

BRX · Q1 2023 → YESThe question is: Does management repeatedly ground its case for the company's future in OPERATING FACTS THAT ARE BOTH FRESH AND EARLY — concrete business developments that (a) began, occurred, or firs...NO The transcript repeatedly references recent leasing activity, occupancy records, and reinvestment deliveries as evidence of momentum, but these are framed as already-visible outcomes from the last quarter rather than fresh developments whose full impact is still ahead. The forward-looking elements—$60 million ABR commenced over the past year, $56 million signed but not commenced, and $38 million in forward pipeline—are explicitly described as commitments whose effects are still to come, not as already-real activity producing measurable results today. Management does not present these as concrete, early-stage facts that have begun contributing in a way that understates the reported period; instead, the case for future 2023 growth rests on guidance adjustments and expectations for continued momentum, which aligns more with industry tailwinds and pipeline size than with the required posture of fresh, already-real developments whose contribution is only beginning.
GECC · Q3 2018 → YESThe question is about whether management repeatedly grounds its case for the company's future in OPERATING FACTS THAT ARE BOTH FRESH AND EARLY. YES The transcript shows management repeatedly anchoring its forward outlook on Avanti’s three newly signed contracts (June, August, and September 2018) — concrete, already-executed deals whose revenue impact is described as “significant revenue growth… ultimately translate into significant and recurring cash flow,” with most of the effect still ahead of the Q3 numbers. This posture is reiterated in both prepared remarks and the Q&A, and Avanti is explicitly called out as the largest portfolio position. No other developments receive comparable emphasis as “fresh and early” operating facts whose contribution remains largely future-weighted. The answer is therefore YES.
BP · Q4 2016 → YESThe question is: Does management repeatedly ground its case for the company's future in OPERATING FACTS THAT ARE BOTH FRESH AND EARLY — concrete business developments that (a) began, occurred, or firs...**YES** Management repeatedly anchors its forward-looking case in concrete, recently realized operating developments that began or became visible only in the last quarter or two of 2016 and are already producing measurable activity today, with the bulk of their contribution still ahead of the reported results. Key examples include: - Six major project start-ups 2016 (In Salah Southern Fields, Point Thomson, Angola LNG, Thunder Horse water injection, Amenas compression, Thunder Horse South Expansion — the last 11 months ahead of schedule and $150 million under budget), already contributing to production and cash flow.

More from the question bank

Sequential re-ratingCustomers coming back on their ownPromise already turning into factAnswers go deeper than the scriptEscape velocity out of a small baseSold before it existsAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.